MX339130B - Formulacion que comprende derivado de fenilaminopirimidina como agente activo. - Google Patents
Formulacion que comprende derivado de fenilaminopirimidina como agente activo.Info
- Publication number
- MX339130B MX339130B MX2013010160A MX2013010160A MX339130B MX 339130 B MX339130 B MX 339130B MX 2013010160 A MX2013010160 A MX 2013010160A MX 2013010160 A MX2013010160 A MX 2013010160A MX 339130 B MX339130 B MX 339130B
- Authority
- MX
- Mexico
- Prior art keywords
- formulation
- nrc
- active agent
- phenylaminopyrimidine derivative
- bcr
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- XGXNTJHZPBRBHJ-UHFFFAOYSA-N n-phenylpyrimidin-2-amine Chemical class N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 title 1
- LCPGCGAJBOWMIP-UHFFFAOYSA-N n-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-3,5-bis(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N=C(C=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LCPGCGAJBOWMIP-UHFFFAOYSA-N 0.000 abstract 2
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 238000004945 emulsification Methods 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 229940100688 oral solution Drugs 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Una formulación farmacéutica oral que contiene una cantidad efectiva de NRCAN-019 incluyendo sus sales farmacéuticamente aceptables y polimorfos tales como Forma I, Forma II y Forma III del mismo para mejorar la biodisponibilidad destinada para auto-emulsificación al hacer contacto con el fluido gastrointestinal. La invención también se refiere a un procedimiento para la preparación de solución oral que contiene NRC-AN-019 en una concentración efectiva para la mejor terapia contra leucemia mieloide crónica como inhibidor de tirosina quinasa de BCR-ABL y contra otros tumores tales como cáncer de cabeza y cuello, cáncer de próstata y similares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1103860.1A GB2488788B (en) | 2011-03-07 | 2011-03-07 | Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response |
| PCT/IB2011/001842 WO2012120328A1 (en) | 2011-03-07 | 2011-08-10 | Formulation comprising phenylaminopyrimidine derivative as active agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013010160A MX2013010160A (es) | 2013-12-06 |
| MX339130B true MX339130B (es) | 2016-05-13 |
Family
ID=43923331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013010160A MX339130B (es) | 2011-03-07 | 2011-08-10 | Formulacion que comprende derivado de fenilaminopirimidina como agente activo. |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9895367B2 (es) |
| EP (1) | EP2683381B1 (es) |
| JP (1) | JP5788534B2 (es) |
| KR (1) | KR101767296B1 (es) |
| CN (1) | CN103561742B (es) |
| AP (1) | AP4076A (es) |
| AU (1) | AU2011361921B2 (es) |
| BR (1) | BR112013022930A2 (es) |
| CA (1) | CA2829015C (es) |
| CO (1) | CO6811851A2 (es) |
| CY (1) | CY1116968T1 (es) |
| DK (1) | DK2683381T3 (es) |
| EA (1) | EA024610B1 (es) |
| ES (1) | ES2554927T3 (es) |
| GB (1) | GB2488788B (es) |
| GE (1) | GEP20156410B (es) |
| HR (1) | HRP20151382T1 (es) |
| HU (1) | HUE025562T2 (es) |
| IL (1) | IL228218A (es) |
| MA (1) | MA35088B1 (es) |
| MX (1) | MX339130B (es) |
| MY (1) | MY158693A (es) |
| NZ (1) | NZ614903A (es) |
| PH (1) | PH12013501844A1 (es) |
| PL (1) | PL2683381T3 (es) |
| PT (1) | PT2683381E (es) |
| RS (1) | RS54420B1 (es) |
| SG (1) | SG193349A1 (es) |
| SI (1) | SI2683381T1 (es) |
| SM (1) | SMT201500235B (es) |
| UA (1) | UA111074C2 (es) |
| WO (1) | WO2012120328A1 (es) |
| ZA (1) | ZA201306643B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62422B1 (sr) * | 2015-12-18 | 2021-10-29 | Natco Pharma Ltd | Farmaceutske kompozicije koje sadrže derivat fenilaminopirimidina |
| EP3397242B1 (en) * | 2015-12-29 | 2021-02-03 | Noivita S.R.L.S. | Lipophilic formulations |
| CN107184549B (zh) * | 2017-04-11 | 2020-11-20 | 江苏大学 | 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法 |
| CN107564610A (zh) * | 2017-10-20 | 2018-01-09 | 浙江中大元通特种电缆有限公司 | 一种陶瓷化硅橡胶绝缘护套不锈钢连锁铠装防火电缆 |
| CA3092238A1 (en) | 2018-03-14 | 2019-09-19 | KaNDy Therapeutics Limited | Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists |
| WO2020151633A1 (en) * | 2019-01-25 | 2020-07-30 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical compositions |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| NZ502569A (en) * | 1997-07-29 | 2002-05-31 | Upjohn Co | Self-emulsifying formulation for lipophilic compounds comprising a mixture of diglyceride and monoglyceride in a ratio of 9:1 to 6:4 |
| US6248354B1 (en) | 1999-03-04 | 2001-06-19 | Allergan Sales, Inc. | Capsule system |
| US7232825B2 (en) * | 2003-05-02 | 2007-06-19 | Guoqing P Chen | Phenylaminopyrimidine derivatives and methods of use |
| EP1498143A1 (en) | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids |
| UA94570C2 (en) * | 2004-09-09 | 2011-05-25 | Натко Фарма Лимитед | Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase |
| MX2008008447A (es) * | 2006-10-26 | 2008-09-15 | Sicor Inc | Proceso para la preparacion de imatinib. |
| EP1920767A1 (en) * | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
| ES2432641T3 (es) * | 2007-04-30 | 2013-12-04 | Intezyne Technologies Inc. | Micelas híbridas de copolímero en bloque con estereoquímica mixta para encapsulación de agentes hidrófobos |
| CA2716413A1 (en) * | 2008-03-04 | 2009-09-11 | Natco Pharma Limited | Crystal form of phenylamino pyrimidine derivatives |
| US8067422B2 (en) | 2008-03-04 | 2011-11-29 | Natco Pharma Limited | Crystal form of phenylamino pyrimidine derivatives |
| US20110160249A1 (en) * | 2008-05-23 | 2011-06-30 | Schaab Kevin Murray | 5-lipoxygenase-activating protein inhibitor |
-
2011
- 2011-03-07 GB GB1103860.1A patent/GB2488788B/en not_active Expired - Fee Related
- 2011-08-10 HR HRP20151382TT patent/HRP20151382T1/hr unknown
- 2011-08-10 MX MX2013010160A patent/MX339130B/es active IP Right Grant
- 2011-08-10 KR KR1020137026440A patent/KR101767296B1/ko not_active Expired - Fee Related
- 2011-08-10 US US14/003,445 patent/US9895367B2/en not_active Expired - Fee Related
- 2011-08-10 AU AU2011361921A patent/AU2011361921B2/en not_active Ceased
- 2011-08-10 EA EA201391280A patent/EA024610B1/ru not_active IP Right Cessation
- 2011-08-10 PL PL11764851T patent/PL2683381T3/pl unknown
- 2011-08-10 NZ NZ614903A patent/NZ614903A/en not_active IP Right Cessation
- 2011-08-10 MY MYPI2013003265A patent/MY158693A/en unknown
- 2011-08-10 CA CA2829015A patent/CA2829015C/en not_active Expired - Fee Related
- 2011-08-10 RS RS20150787A patent/RS54420B1/sr unknown
- 2011-08-10 JP JP2013557180A patent/JP5788534B2/ja not_active Expired - Fee Related
- 2011-08-10 HU HUE11764851A patent/HUE025562T2/en unknown
- 2011-08-10 BR BR112013022930A patent/BR112013022930A2/pt not_active IP Right Cessation
- 2011-08-10 ES ES11764851.9T patent/ES2554927T3/es active Active
- 2011-08-10 AP AP2013007128A patent/AP4076A/en active
- 2011-08-10 CN CN201180069095.7A patent/CN103561742B/zh not_active Expired - Fee Related
- 2011-08-10 EP EP11764851.9A patent/EP2683381B1/en active Active
- 2011-08-10 PT PT117648519T patent/PT2683381E/pt unknown
- 2011-08-10 SI SI201130592T patent/SI2683381T1/sl unknown
- 2011-08-10 PH PH1/2013/501844A patent/PH12013501844A1/en unknown
- 2011-08-10 GE GEAP201113254A patent/GEP20156410B/en unknown
- 2011-08-10 SG SG2013067319A patent/SG193349A1/en unknown
- 2011-08-10 WO PCT/IB2011/001842 patent/WO2012120328A1/en not_active Ceased
- 2011-08-10 DK DK11764851.9T patent/DK2683381T3/en active
- 2011-10-08 UA UAA201310715A patent/UA111074C2/uk unknown
-
2013
- 2013-09-01 IL IL228218A patent/IL228218A/en active IP Right Grant
- 2013-09-04 ZA ZA2013/06643A patent/ZA201306643B/en unknown
- 2013-09-09 MA MA36236A patent/MA35088B1/fr unknown
- 2013-10-04 CO CO13236457A patent/CO6811851A2/es unknown
-
2015
- 2015-09-29 SM SM201500235T patent/SMT201500235B/xx unknown
- 2015-11-26 CY CY20151101069T patent/CY1116968T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ630457A (en) | Compounds useful as inhibitors of atr kinase | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
| MY149731A (en) | Compounds | |
| PH12013501594A1 (en) | Substituted indazole derivatives active as kinase inhibitors | |
| PH12016500164A1 (en) | Therapeutically active compounds and their methods of use | |
| CO6781534A2 (es) | Sales de 2,3-dihidroimidazol[1,2-c]quinazolina substituida | |
| WO2013052699A3 (en) | Novel quinoxaline inhibitors of pi3k | |
| MX365702B (es) | Inhibidores de pirazolil quinoxalina cinasa. | |
| SI2324008T1 (sl) | 3,4-diarilpirazoli kot protein-kinazni inhibitorji | |
| NZ601595A (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
| MX2013010160A (es) | Formulacion que comprende derivado de fenilaminopirimidina como agente activo. | |
| WO2012159085A3 (en) | Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells | |
| MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| MX2009013835A (es) | Forma de dosis estabilizada de picoplatino. | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| WO2011056021A3 (ko) | 벤조헤테로사이클 유도체의 암 예방 및 치료 또는 암 전이 억제를 위한 용도 | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| MX371119B (es) | Productos de combinacion con los inhibidores de cinasa de tirosina y su uso. | |
| PH12018501292A1 (en) | Pharmaceutical compositions comprising phenylaminopyridine derviative | |
| MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
| JP2014530181A5 (es) | ||
| WO2013055913A3 (en) | Pgam1 inhibitors and methods related thereto | |
| RU2012115039A (ru) | Способ лечения хронического эндометрита | |
| NZ629800A (en) | (1r,4r)-6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro-[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for treating fibromyalgia and chronic fatigue syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |